



Illinois Prescription Monitoring Program April 2026 Update



Subscribe to @ILPMP on YouTube

[Click for ILPMP New Website Announcement](#)


UPDATES



IDPH Poisoning/Overdose Data Goes Live on ILPMP Website

In April, the Illinois Department of Public Health (IDPH) Poisoning/Overdose dataset was officially integrated into the ILPMP website, expanding the tools available to support clinical decision-making and enhance patient safety.

This new feature (pictured below) provides visibility into a patient's history of drug poisoning or overdose events resulting in hospital treatment. The dataset includes key indicators such as the presence of opioids, stimulants, or benzodiazepines, as well as whether the event was fatal. By incorporating this information directly into ILPMP, prescribers and pharmacists have a more comprehensive view of patient risk factors at the point of care.




CDC Health Advisory Announces Medetomidine in U.S. Illegal Fentanyl Supply Increasing Risk for Overdose

The Centers for Disease Control and Prevention (CDC), in conjunction with the White House Office of National Drug Control Policy (ONDCP), is issuing this Health Advisory to notify public health professionals, clinicians, laboratorians, and people at risk for overdose about increasing reports from U.S. jurisdictions detecting medetomidine in the illegal drug supply and a severe withdrawal syndrome due to medetomidine exposure. Medetomidine (also known as 'rhino tranquilizer,' 'mede,' or 'dex') is not approved for human use but is approved for sedation and analgesia in dogs. Its dextro-isomer, dexmedetomidine, is approved for procedural sedation in humans.

Read Full Press Release

ILPMP Data Dashboards Now Include 2025 Data



The ILPMP Data Dashboards now feature expanded reporting through 2025, offering insights into prescribing trends and patient activity across Illinois. Newly published dashboards include county-level trends on buprenorphine utilization, multiple provider episodes, and updated counts of opioid patients and prescriptions. The *Prescription Statistics By Drug Type* dashboard now provides a broader view of controlled substance categories which includes opioids, fentanyl, ketamine, benzodiazepines, and stimulants.

Is Sharing of an ILPMP Account Authorized?




No, sharing of an ILPMP account is not authorized. ILPMP does allow authorized designees to register for a website account to search on the prescriber's or pharmacist's behalf. See [Frequently Asked Questions](#) for more details.

Advancing Patient Safety Through ILPMP Education



On April 14, 2026, the North Suburban Pharmacists of Chicagoland hosted a continuing education program on the ILPMP at Bar Siena in Skokie, Illinois. The evening included networking, a sponsor presentation from Abbott Diabetes Care, and an educational session led by Barbara Sauer, Rph., ILPMP Clinical Project Manager. This educational session focused on using ILPMP data to support safe prescribing and patient care. The continued education program, sponsored by the Illinois Pharmacist Association, highlighted pharmacists' role in improving patient safety and addressing the opioid crisis.





Long Term Care Pharmacy Reporting Expectations

Illinois Prescription Monitoring Program (ILPMP)

This presentation was recorded February 2025 by the Illinois Prescription Monitoring Programs Pharmacy Compliance Team on Long Term Care reporting.

What you will learn:

- Daily Versus Weekly Reporting
- Retail Versus Long Term Care (LTC) Pharmacies
- Civil Fines
- Data Submitters Guide and ASAP 5.0 LTC Reporting
- DSP22 Update and Chart Orders



Daily Reporting Requirements:

- All Schedule II-V Controlled Substances
- Drugs of Interest, by medication class:

Butalbital Combination Products

Gabapentin

Muscle Relaxants

Opioid Antagonists

Weekly Long Term Care Reporting Requirements:

- SECTION 2081.APPENDIX A NAME OF MEDICATIONS FOR PRESCRIPTION MONITORING PROGRAM - LONG TERM CARE REPORTING

Please contact the Pharmacy Compliance Team at DHS.DBHR.PharmacyCompliance@Illinois.gov with any questions.

VIRTUAL ASK THE EXPERT SERIES

OPIOID TAPERING STRATEGIES

FREQUENCY ASKED QUESTIONS
MAY 14TH, 12:00PM CST

PRESENTED BY:
SCOTT E. GLASER, MD, DABIPP
CEO & PRESIDENT
PAIN SPECIALISTS OF GREATER CHICAGO



MODERATED BY:
CHRIS HERNDON, PHARM D
PROFESSOR, SIUE



<https://tinyurl.com/ms7dkr6h>

NOTE THIS SESSION IS NOT APPROVED FOR CONTINUING EDUCATION

This informal discussion, led by Scott Glaser, will explore practical approaches to opioid tapering in patients with chronic pain, emphasizing individualized care, patient-centered communication, and risk mitigation. Dr. Glaser will share clinical insights on when and how to initiate a taper, strategies to minimize withdrawal symptoms, and methods to maintain therapeutic alliance while addressing concerns such as opioid use disorder, functional outcomes, and quality of life. The session will encourage open dialogue among participants, allowing for the exchange of real-world experiences, challenges, and best practices in implementing safe and effective opioid tapering plans across diverse patient populations.

[Click To Register](#)

EDUCATIONAL RESOURCES

The Safe Opioid Prescribing Series

Target Audience: Prescribers and Pharmacists

Cost: FREE

Register for (10) 30-minute online modules collectively fulfilling 5 hours CME credit.

[Register For CME Modules](#)

Navigating Pain Management, Safe Opioid Prescribing, Opioid Use Disorder

Target Audience: Pharmacists

Cost: FREE

Register for (10) 30-minute online modules collectively fulfilling 5 hours CE credit.

[Register for CE Modules](#)

Data Quality in Prescription Monitoring Programs

Target Audience: Pharmacists, Pharmacy Technicians, Dispensing Practitioners, and any other Data Submitters

Cost: FREE


Free ACPE accredited educational opportunity providing 1 hour of continuing education for pharmacists and pharmacy technicians. This program, developed in partnership with NASCSA and 12 prescription monitoring program (PMP)

administrators, analyzes the importance and value of complete, accurate data reported by dispensers to PMPs and assesses the impact of intentional or non-intentional data entry errors and data omissions on patient safety. It also discusses the downstream impacts of pharmacy-reported PMP data on clinical decision-making processes and helps pharmacy staff identify and implement changes that can be made in their practice setting to improve PMP data integrity. **If you received credit for this CE prior to 10/20/25, this CE opportunity is available to you again to participate in and receive credit.**

<https://ce.talemhealth.com/a/LPMBSE>

[Register For CE](#)

ILPMP.ORG & Illinois PMPnow Monthly Data Totals



CONTACT US

✉ DHS.DBHR.PharmacyCompliance@illinois.gov
✉ DHS.DBHR.PMPnow@illinois.gov
✉ DHS.PMP@illinois.gov
🌐 ILPMP.ORG



The Illinois Prescription Monitoring Program (ILPMP) is an electronic database that collects, tracks, and stores reported dispensing data on Schedule II-V controlled substances, selected drugs of interest, and other health information. The Illinois Department of Human Services oversees the ILPMP, authorized by the Illinois Controlled Substances Act (720 ILCS 570/316). The ILPMP adheres to HIPAA and all access, disclosure, and confidentiality provisions of Illinois Law.

Illinois Prescription Monitoring Program | 401 North 4th Street | Springfield, IL 62702 US

[Unsubscribe](#) | [Update Profile](#) | [Constant Contact Data Notice](#)



Try email & social marketing for free!